Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Dean

Showing results (1-10 of 248) with videos related to

Pageof 25
Sort By:
The International Journal of Neuropsychopharmacology|December 16, 2010
Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studiesBrian Dean
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 22, 2004
M1 receptor agonism, a possible treatment for cognitive deficits in schizophreniaBrian Dean
The Australian and New Zealand Journal of Psychiatry|December 17, 2008
Is schizophrenia the price of human central nervous system complexity?Brian Dean
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 25, 2009
Interpreting the significance of decreased cortical serotonin 2A receptors in schizophreniaBrian Dean
The Australian and New Zealand Journal of Psychiatry|February 14, 2004
The neurobiology of bipolar disorder: findings using human postmortem central nervous system tissueBrian Dean
Schizophrenia Research|February 14, 2013
Epigenetic mechanisms and the serotonin 2A receptor in schizophreniaBrian Dean
The Australian and New Zealand Journal of Psychiatry|November 8, 2017
Irreproducible data: Problems and solutions for psychiatryBrian Dean
Expert Opinion on Investigational Drugs|November 23, 2023
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenalBrian Dean
Journal of Neurochemistry|March 19, 2003
The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accompliceBrian Dean
Future Medicinal Chemistry|September 13, 2013
Cholinergic muscarinic receptors: new opportunities to treat psychiatric disordersBrian Dean
Pageof 25

Showing results (1-10 of 248) with videos related to

Sort By:
Pageof 25
The International Journal of Neuropsychopharmacology|December 16, 2010
Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studiesBrian Dean
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 22, 2004
M1 receptor agonism, a possible treatment for cognitive deficits in schizophreniaBrian Dean
The Australian and New Zealand Journal of Psychiatry|December 17, 2008
Is schizophrenia the price of human central nervous system complexity?Brian Dean
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 25, 2009
Interpreting the significance of decreased cortical serotonin 2A receptors in schizophreniaBrian Dean
The Australian and New Zealand Journal of Psychiatry|February 14, 2004
The neurobiology of bipolar disorder: findings using human postmortem central nervous system tissueBrian Dean
Schizophrenia Research|February 14, 2013
Epigenetic mechanisms and the serotonin 2A receptor in schizophreniaBrian Dean
The Australian and New Zealand Journal of Psychiatry|November 8, 2017
Irreproducible data: Problems and solutions for psychiatryBrian Dean
Expert Opinion on Investigational Drugs|November 23, 2023
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenalBrian Dean
Journal of Neurochemistry|March 19, 2003
The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accompliceBrian Dean
Future Medicinal Chemistry|September 13, 2013
Cholinergic muscarinic receptors: new opportunities to treat psychiatric disordersBrian Dean
Pageof 25